We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-15.77%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$181M
AUM Growth
+$54.8M
Cap. Flow
+$26.4M
Cap. Flow %
14.57%
Top 10 Hldgs %
55.68%
Holding
69
New
12
Increased
29
Reduced
12
Closed
12

Top Buys

Rank Stock Value
1
IBB icon
iShares Biotechnology ETF
IBB
+$7.2M
2
AGIO icon
Agios Pharmaceuticals
AGIO
+$4.5M
3
MDVN
MEDIVATION, INC.
MDVN
+$2.46M
4
BMY icon
Bristol-Myers Squibb
BMY
+$2.28M
5
MRK icon
Merck
MRK
+$2.28M

Top Sells

Rank Stock Value
1
RCPT
RECEPTOS INC COM STK (DE)
RCPT
+$5.34M
2
BIB icon
ProShares Ultra NASDAQ Biotechnology
BIB
+$1.78M
3
TSRO
TESARO, Inc.
TSRO
+$1.76M
4
PCRX icon
Pacira BioSciences
PCRX
+$1.59M
5
ESPR
Esperion Therapeutics
ESPR
+$1.23M

Sector Composition

Rank Sector Weight
1 Healthcare 59.5%
2 Miscellaneous 40.37%
3 Financials 0.14%
4 Consumer Staples 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BIB icon
26
ProShares Ultra NASDAQ Biotechnology
BIB
$105M
$1.91M 1.05%
32,717
-20,851
-39% -$1.78M
HOLX
27
DELISTED
Hologic
HOLX
$1.88M 1.04%
48,000
– –
NSTG
28
DELISTED
NanoString Technologies, Inc.
NSTG
$1.64M 0.9%
102,200
+42,200
+70% +$661K
ARRY
29
DELISTED
Array Biopharma Inc
ARRY
$1.14M 0.63%
250,000
-70,000
-22% -$415K
AVDL
30
DELISTED
Avadel Pharmaceuticals
AVDL
$926K 0.51%
56,788
+5,000
+10% +$110K
VCEL icon
31
Vericel Corp
VCEL
$2.11B
$900K 0.5%
332,157
-30,000
-8% -$98.5K
ZGNX
32
DELISTED
Zogenix, Inc.
ZGNX
$887K 0.49%
65,700
+28,200
+75% +$509K
PCRX icon
33
Pacira BioSciences
PCRX
$1.03B
$863K 0.48%
21,000
-26,000
-55% -$1.59M
AMGN icon
34
Amgen
AMGN
$236B
$778K 0.43%
5,626
+76
+1% +$12K
CRIS icon
35
Curis
CRIS
$3.64M
$756K 0.42%
187
+79
+73% +$447K
ACHN
36
DELISTED
Achillion Pharmaceuticals
ACHN
$733K 0.4%
106,104
+39,400
+59% +$321K
UTHR icon
37
United Therapeutics
UTHR
$22.6B
$731K 0.4%
5,571
+172
+3% +$27.6K
NVAX icon
38
CALL
Novavax
NVAX
$1.49B
$707K 0.39%
+5,000
New +$1.12M
NVAX icon
39
PUT
Novavax
NVAX
$1.49B
$707K 0.39%
+5,000
New +$1.12M
STML
40
DELISTED
Stemline Therapeutics, Inc.
STML
$662K 0.37%
75,000
– –
EPZM
41
DELISTED
Epizyme, Inc
EPZM
$593K 0.33%
46,079
-26,300
-36% -$531K
CMRX
42
DELISTED
Chimerix, Inc.
CMRX
$541K 0.3%
14,152
-5,000
-26% -$247K
MACK
43
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$528K 0.29%
7,881
-1,271
-14% -$104K
RPRX
44
CALL
DELISTED
Repros Therapeutics Inc.
RPRX
$494K 0.27%
+98,000
New +$749K
GILD icon
45
Gilead Sciences
GILD
$185B
$424K 0.23%
4,323
+89
+2% +$9.88K
SIOX
46
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$397K 0.22%
+3,840
New +$450K
INFI
47
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$383K 0.21%
45,300
-34,700
-43% -$320K
ARWR icon
48
Arrowhead Research
ARWR
$12.5B
$295K 0.16%
51,133
-31,000
-38% -$195K
ISEE
49
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$290K 0.16%
+7,150
New +$379K
NHLD
50
DELISTED
National Holdings Corporation
NHLD
$246K 0.14%
89,530
– –
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2015 Portfolio in Review

As of Q3 2015, Opus Point Partners Management held 69 positions worth $181M, up 43% from $126M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Opus Point Partners Management deployed $26.4M of net new capital in Q3 2015, opening 12 new positions and adding to 29 existing holdings. Its largest new stake was iShares Biotechnology ETF: 60,000 shares worth $6.07M.

By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 83% a quarter earlier, followed by Miscellaneous and Financials.

On the sell side, the largest reduction was ProShares Ultra NASDAQ Biotechnology, an estimated $1.78M trimmed.

  • Opus Point Partners Management's largest Q3 2015 buy was iShares Biotechnology ETF: 60,000 shares worth $6.07M.
  • Opus Point Partners Management added most to MEDIVATION, INC. in Q3 2015, an estimated $2.46M increase.
  • Opus Point Partners Management's biggest Q3 2015 reduction was ProShares Ultra NASDAQ Biotechnology, cutting an estimated $1.78M.
  • Opus Point Partners Management fully exited RECEPTOS INC COM STK (DE) in Q3 2015, selling an estimated $5.34M.
  • Opus Point Partners Management's ten largest holdings make up 56% of its $181M portfolio in Q3 2015.
  • Opus Point Partners Management opened 12 new positions and closed 12 in Q3 2015.
  • Opus Point Partners Management's portfolio value rose 43% quarter-over-quarter to $181M.

Based on Opus Point Partners Management's 13F filing for Q3 2015, filed 16 Nov 2015.